Business
Positive SRA737 data presented at ASCO
Positive SRA737 data presented at ASCO.
About this update from Sareum Holdings Plc
[{"type":"text","content":"\n \nRNS Number : 8467A Sareum Holdings PLC 03 June 2019 \n\n\n\n\n(AIM: SAR)\n\n\n3 June 2019\n\n\n\n \nThis announcement contains inside information for the purposes of Article 7 of regulation 596/2014\nSareum Holdings PLC\n(\"Sareum\" or the \"Company\")\n \nSareum notes that positive preliminary efficacy data from Phase 1/2 clinical trials with SRA737 in advanced cancer were presented at ASCO 2019 - potential path to registration outlined\n· 30% response rate for SRA737 + low dose gemcitabine (LDG) in anogenital cancer\n· Anti-cancer activity demonstrated across multiple indications and genetic profiles\n· Sierra Oncology to discuss clinical findings and next steps for SRA737 at Analyst & Investor Event and live webcast today at 12:00 BST\nSareum Holdings plc (AIM: SAR), the specialist small molecule drug development business, notes that Sierra Oncology (the licence holder for Chk1 inhibitor SRA737) reported positive preliminary clinical data from its two first-in-human Phase 1/2 studies of SRA737 as monotherapy and as SRA737+LDG (SRA737 potentiated by low dose gemcitabine) at the 2019 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL. Anti-cancer activity was demonstrated across multiple indications and genetic contexts, with SRA737+LDG specifically achieving a notable 30% response rate in anogenital cancer patients.\n \nThe data and further analyses can be found in the announcement made on Saturday 1 June by Sierra Oncology (click here) and in both posters, which are available here. A live webcast of the Analyst & Investor Event taking place today at 12:00 BST can be accessed by clicking here. \n \nDr Tim Mitchell, CEO of Sareum Holdings, said: \"We are extremely encouraged by the preliminary clinical data that Sierra announced from its clinical programme with SRA737 at ASCO over the weekend. The results demonstrate the exciting potential of SRA737 in patients whose cancer type and genetic profile may confer and enhance sensitivity to this novel drug candidate, and open pathways for its advancement into the next stages of development towards registration. We look forward to providing updates on this exciting prospect as further progress is made and important development milestones are reached.\"\n \n...